MX394259B - Compuestos inhibidores de tirosina cinasa de bruton (btk) - Google Patents

Compuestos inhibidores de tirosina cinasa de bruton (btk)

Info

Publication number
MX394259B
MX394259B MX2020004435A MX2020004435A MX394259B MX 394259 B MX394259 B MX 394259B MX 2020004435 A MX2020004435 A MX 2020004435A MX 2020004435 A MX2020004435 A MX 2020004435A MX 394259 B MX394259 B MX 394259B
Authority
MX
Mexico
Prior art keywords
bruton
btk
inhibitor compounds
tyrosine kinase
compounds
Prior art date
Application number
MX2020004435A
Other languages
English (en)
Other versions
MX2020004435A (es
Inventor
Albert Khilevich
Katherine Marie Partridge
Jr Kenneth James Henry
Steven James Quimby
Steven Lee Kuklish
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2020004435A publication Critical patent/MX2020004435A/es
Publication of MX394259B publication Critical patent/MX394259B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a compuestos inhibidores de BTK, sales farmacéuticamente aceptables, composiciones farmacéuticas de los mismos, y métodos para usar estos compuestos, sales, o composiciones para tratar enfermedades autoinmunes tales como Artritis Reumatoide.
MX2020004435A 2017-11-06 2018-10-30 Compuestos inhibidores de tirosina cinasa de bruton (btk) MX394259B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762581967P 2017-11-06 2017-11-06
PCT/US2018/058104 WO2019089512A1 (en) 2017-11-06 2018-10-30 Btk inhibitor compounds

Publications (2)

Publication Number Publication Date
MX2020004435A MX2020004435A (es) 2020-08-06
MX394259B true MX394259B (es) 2025-03-24

Family

ID=64277913

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004435A MX394259B (es) 2017-11-06 2018-10-30 Compuestos inhibidores de tirosina cinasa de bruton (btk)

Country Status (36)

Country Link
US (1) US11542249B2 (es)
EP (1) EP3707133B1 (es)
JP (1) JP6920553B2 (es)
KR (1) KR102410202B1 (es)
CN (1) CN111278818B (es)
AR (1) AR113796A1 (es)
AU (1) AU2018360478B2 (es)
BR (1) BR112020006749A2 (es)
CA (1) CA3080123C (es)
CL (1) CL2020001089A1 (es)
CR (1) CR20200183A (es)
CY (1) CY1124994T1 (es)
DK (1) DK3707133T3 (es)
DO (1) DOP2020000103A (es)
EA (1) EA039398B1 (es)
EC (1) ECSP20024395A (es)
ES (1) ES2904843T3 (es)
HR (1) HRP20220178T1 (es)
HU (1) HUE057987T2 (es)
IL (1) IL273778B (es)
JO (1) JOP20200104A1 (es)
LT (1) LT3707133T (es)
MA (1) MA50561B1 (es)
MD (1) MD3707133T2 (es)
MX (1) MX394259B (es)
MY (1) MY198424A (es)
PE (1) PE20201168A1 (es)
PH (1) PH12020550791B1 (es)
PL (1) PL3707133T3 (es)
PT (1) PT3707133T (es)
RS (1) RS62805B1 (es)
SG (1) SG11202003178PA (es)
SI (1) SI3707133T1 (es)
TW (1) TWI694995B (es)
UA (1) UA126079C2 (es)
WO (1) WO2019089512A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3972603T (pt) 2019-05-23 2024-11-26 Novartis Ag Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2701275C (en) * 2007-10-23 2016-06-21 F. Hoffmann-La Roche Ag Kinase inhibitors
EP2566869B1 (en) * 2010-05-07 2016-03-02 Gilead Connecticut, Inc. Pyridone and aza-pyridone compounds and methods of use
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
KR20180084153A (ko) 2011-06-10 2018-07-24 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
WO2014093230A2 (en) * 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
GB2516303A (en) * 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
US10526309B2 (en) * 2015-10-02 2020-01-07 The University Of North Carolina At Chapel Hill Pan-TAM inhibitors and Mer/Axl dual inhibitors

Also Published As

Publication number Publication date
HUE057987T2 (hu) 2022-06-28
CR20200183A (es) 2020-05-30
AU2018360478B2 (en) 2020-09-17
JP6920553B2 (ja) 2021-08-18
JP2021501749A (ja) 2021-01-21
TWI694995B (zh) 2020-06-01
CA3080123C (en) 2021-11-09
AR113796A1 (es) 2020-06-10
KR20200060480A (ko) 2020-05-29
MY198424A (en) 2023-08-29
US20200290997A1 (en) 2020-09-17
UA126079C2 (uk) 2022-08-10
RS62805B1 (sr) 2022-02-28
PT3707133T (pt) 2022-01-27
KR102410202B1 (ko) 2022-06-22
EA202090843A1 (ru) 2020-07-24
ECSP20024395A (es) 2020-06-30
CA3080123A1 (en) 2019-05-09
IL273778A (en) 2020-05-31
CY1124994T1 (el) 2023-01-05
PH12020550791A1 (en) 2021-04-12
PH12020550791B1 (en) 2024-04-17
MD3707133T2 (ro) 2022-07-31
EA039398B1 (ru) 2022-01-24
LT3707133T (lt) 2022-01-25
HRP20220178T1 (hr) 2022-04-29
MA50561A (fr) 2020-09-16
CN111278818A (zh) 2020-06-12
CN111278818B (zh) 2023-03-28
NZ764452A (en) 2023-09-29
SG11202003178PA (en) 2020-05-28
EP3707133A1 (en) 2020-09-16
US11542249B2 (en) 2023-01-03
DK3707133T3 (da) 2022-01-03
DOP2020000103A (es) 2020-09-15
JOP20200104A1 (ar) 2022-10-30
EP3707133B1 (en) 2021-12-15
PE20201168A1 (es) 2020-10-28
AU2018360478A1 (en) 2020-04-23
BR112020006749A2 (pt) 2020-10-06
MX2020004435A (es) 2020-08-06
MA50561B1 (fr) 2022-03-31
WO2019089512A1 (en) 2019-05-09
CL2020001089A1 (es) 2020-10-23
TW201930293A (zh) 2019-08-01
SI3707133T1 (sl) 2022-02-28
PL3707133T3 (pl) 2022-04-04
IL273778B (en) 2022-06-01
ES2904843T3 (es) 2022-04-06

Similar Documents

Publication Publication Date Title
MX388457B (es) Inhibidores de imidazopirazina de la tirosina cinasa de bruton.
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
EA201892207A1 (ru) Индолкарбоксамидные соединения
EA202091709A1 (ru) Ингибиторы днк-пк
EA202091708A1 (ru) Ингибиторы днк-пк
MX383213B (es) Inhibidores de tirosina-cinasas
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201992128A1 (ru) Конденсированные имидазопиперидиновые ингибиторы jak
EA201892436A1 (ru) Пиримидиновые соединения в качестве ингибиторов jak киназы
ZA201907746B (en) 6-5 fused rings as c5a inhibitors
EA201990400A1 (ru) Соединения и композиции и их применение
TN2017000158A1 (en) Carbazole derivatives
MX391392B (es) ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES C5a.
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
EA201790870A1 (ru) Трициклические атропоизомерные соединения
MX2021013602A (es) Inhibidores de jak.
MX394259B (es) Compuestos inhibidores de tirosina cinasa de bruton (btk)
BR112022005608A2 (pt) Inibidores de jak
EA202190766A1 (ru) Иммуномодуляторы, их композиции и способы применения
EA202092446A1 (ru) ТИАЗОЛ- ИЛИ ТИАДИАЗОЛЗАМЕЩЕННЫЕ АРИЛЬНЫЕ И ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ Vps34
EA201792676A1 (ru) Ингибиторы jak1
EA201791450A1 (ru) 3,5-диаминопиразоловые ингибиторы киназы
BR112022002390A2 (pt) Inibidores de jak